市場調查報告書
商品編碼
1352140
全球心內超音波心動圖設備市場 - 2023-2030Global Intracardiac Echocardiography Devices Market - 2023-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
心內超音波心動圖 (ICE) 利用聲波以與經胸超音波心動圖或「標準」超音波心動圖完全相同的方式建構心臟影像。然而,透過心內超音波心動圖檢查,將帶有超音波感測器的小導管插入心臟,可以獲得完美的心臟影像,以幫助診斷和治療特殊的心臟疾病。
心內超音波心動圖(ICE) 是一種獨特的導管成像技術,通常用於輔助房間隔缺損(ASD)、卵圓孔未閉(PFO) 和室間隔缺損(VSD) 的閉合技術,這些干預措施專門作為心臟直視手術進行幾年前。心內超音波心動圖廣泛用於指導結構性心臟病和心律不整的經導管干預,以簡化手術成功並最大限度地減少複雜性。
心血管疾病病例的增加、合併、收購、產品推出等市場發展、意識的提高等因素預計將推動預測期內全球心內超音波心動圖設備市場的成長。此外,不斷成長的研究活動、技術進步以及心內超音波心動圖設備的資金投入預計也將促進預測期內全球市場的成長。
動力學
心血管疾病盛行率增加
心血管疾病病例的增加是預計在預測期內推動全球市場成長的主要因素之一。例如,根據歐洲心血管協會的數據,在 ESC 相關國家,每年有超過 1,260 萬人患有 CVD。心血管疾病是 ESC 成員國男性死亡的首要原因 (39%),而 ESC 夥伴國家每年有 220 萬名女性因心血管疾病死亡,歐盟約有 40% 的女性死於心血管疾病。
此外,根據英國心臟基金會2023 年4 月發布的英國情況說明書,英國約有760 萬人患有心臟和循環系統疾病,人口老化和人口成長以及心臟和循環系統疾病存活率的提高可能會見證這些數字進一步成長。英國約有400萬男性和超過360萬名女性患有心臟和循環系統疾病,據估計,英國超過一半的居民在其一生中會遇到心臟或循環系統疾病。
此外,英國患有心臟和循環系統疾病的人數大約是癌症和阿茲海默症病例數量的兩倍。在英國,心臟和循環系統疾病約佔所有死亡人數的 25%;每年有超過 16 萬人死亡,或每天 460 人死亡,每三分鐘就有 1 人死亡,英國每年約有 48,000 名 75 歲以下的人死於心臟和循環系統疾病。
產品核准數量不斷增加
預計不同監管機構批准的產品數量不斷增加也將有助於預測期內全球心內超音波心動圖設備市場的成長。例如,2022 年4 月,Franklin Mountain Medical 獲得了FDA 對其專利UltraNav 房間隔導管系統的授權,這是一種雙腔導管,允許通過一個雙腔設備並排、同時輸送ICE 和房間隔針或導管,用於治療透過房間隔穿刺將心血管導管和導絲穩定地進入和輸送至心室。
同樣,2021 年6 月,西門子Healthineers 的AcuNav Volume ICE(心內超音波心動圖)導管獲得了CE 標誌,這是一種支持治療的成像指南,可在結構性心臟和電生理學操作中提供心臟解剖結構的即時、廣角可視化。 AcuNav Volume ICE 是市場上最重要的 Volume ICE 導管,其設計基於 ICE 20 年的創新記錄。
心內超音波心動圖設備成本高
心內超音波心動圖設備和導管的高成本預計將阻礙預測期內全球心內超音波心動圖設備市場的成長。例如,根據購買的導管數量,相控陣 ICE 導管的成本從 2,000 美元到 2,500 美元不等。同樣,心臟 3D 測繪系統的平均清單成本從 25 萬美元到 80 萬美元不等。
同樣,Boston Scientific 的 iLAB 心內成像超音波成像系統售價約為 131,400 美元。此外,心內超音波心動圖導管系統的平均成本(2000-2500美元)是心內超音波心動圖普遍使用的重要障礙,減緩了預測期內全球心臟超音波設備的市場需求。
心臟科醫師勞動力短缺
預計心臟科專家的勞動力缺口將阻礙預測期內全球心內超音波心動圖設備市場的成長。例如,根據美國心臟病學會基金會的說法,由於沒有足夠的臨床醫生來滿足不斷成長的患者群體的需求,心臟病學專業領域正處於令人擔憂的邊緣。同樣,根據高收入國家歐洲心臟病學會的數據,每百萬居民中心臟科醫生的中位數為 99.0 人,而中等收入國家為 61.1 人。
此外,根據印度心臟學會 (CSI) 的數據,在該國 13 億人口中,只有 5500 名心臟病專家,而該國 30, 000 名居民中只有一名心臟病專家。同樣,根據美國醫學院協會 (AAMC) 最近的一項調查,到 2034 年,預計美國將缺乏 37,000 至 124,000 名醫務人員。其中包括 17,000 至 48,000 名基層醫療醫師和 3,000 至 13,000 名專家(其中包括心臟病專家)的缺口。
Intracardiac Echocardiography (ICE) utilizes sound waves to construct pictures of the heart in the exact manner that a transthoracic or "standard" echocardiogram accomplishes. Nevertheless, with intracardiac echocardiography, a small catheter with an ultrasound sensor is inserted into the heart where perfect pictures of the heart can be acquired to aid in diatinct cardiological condition diagnosis and management.
The Intracardiac Echocardiography (ICE) is a unique catheter imaging technology usually utilized to aid closure techniques for atrial septal defects (ASD), patent foramen ovale (PFO), and ventricular septal defects (VSD), interventions exclusively conducted as open-heart surgical operations a few years ago. Intracardiac echocardiography is vastly employed to direct transcatheter interventions for structural cardiac disorder and arrhythmia, to streamline procedural success and minimize intricacies.
The growing cases of cardiovascular disorders, market developments including mergers, acquisitions, products introductions among others, growing awareness among other factors are expected to boost the global intracardiac echocardiography devices market growth in the forecast period. Further, the growing research activities, technological advancements and with fundings in intracardiac echocardiography devices are also expected to contribute to the global market growth in the forecast period.
Dynamics
Increasing Prevalence of Cardiovascular Disorders
The growing cases of cardiovascular condition is among the primary factor that is expected to boost the global market growth in the forecast period. For instance, according to the European Cardiovascular Society, over 12.6 million individuals suffer from CVD each year in ESC-associated nations. The cardiovascular condition is the top reason for mortality (39%) among men in ESC member nations while 2.2 million females die because of cardiovascular condition annually in ESC associate nations around 40% of women die from CVD in the EU.
Also, according to the British Heart Foundation Released UK Factsheet in April 2023, around 7.6 million individuals are living with heart and circulatory disorders in the UK, aging and growing inhabitants and enhanced survival rates from heart and circulatory events could witness these numbers advance still additionally. About 4 million men and over 3.6 million women are living with heart and circulatory conditions in the UK, it is estimated that in the UK over half of inhabitants will encounter heart or circulatory disorders in their lifespan.
Moreover, approximately double the number of individuals living with heart and circulatory conditions in the UK compared to the number of cancer and Alzheimer's conditions cases added. Heart and circulatory disorders generate about 25% of all deaths in the UK; that's over 160,000 deaths annually, or 460 every day accounting for one death every three minutes, roughly 48,000 individuals below the age of 75 in the UK die because of heart and circulatory disorders every year.
Increasing Number of Product Approvals
The rising number of product approvals by distinct regulatory authorities is also expected to contribute to the global intracardiac echocardiography devices market growth during the forecast period. For instance, in April 2022, Franklin Mountain Medical obtained FDA authorization for its patented UltraNav Transseptal Catheter System a dual-lumen catheter that allows side-by-side, concurrent delivery of both ICE and transseptal needles or catheters via one dual-lumen device for steady access and delivery of cardiovascular catheters and guidewires to the cardiac chambers through transseptal puncture.
Similarly, in June 2021, Siemens Healthineers acquired CE Mark for the AcuNav Volume ICE (Intracardiac Echocardiography) catheter, a therapy-enabling imaging guide that delivers real-time, wide-angle visualization of cardiac anatomy in Structural Heart and Electrophysiology operations. AcuNav Volume ICE was the market's foremost Volume ICE catheter, designed based on 20 years of innovation record in ICE.
High Intracardiac Echocardiography Device Cost
The high intracardiac echocardiography devices and catheter costs are expected to be hampering the global Intracardiac Echocardiography Devices market growth during the forecast period. For instnace, the cost of a phased-array ICE catheter varies from $2,000 to $2,500, based on the volume of catheters bought. Similarly, the average list cost of cardiac 3D mapping systems varies from USD 250,000 to 800,000.
Likewise, Boston Scientific's iLAB Ultrasound Imaging System for Intracardiac Imaging costs around $131,400. Further, the average cost of a intracardiac echocardiography catheter system (USD 2000-2500) is an important barrier to the general usage of intracardiac echocardiography, slowing the global intracardiac echocardiography devices market demand in the forecast period.
Cardiologists Workforce Shortage
The cardiologists' workforce gap is expected to hamper the global intracardiac echocardiography devices market growth during the forecast period. For instance, according to the American College of Cardiology Foundation with not sufficient clinicians available to satisfy the requirements of an ever-growing patient population, the cardiology specialty domain is on the cusp of a concern. Similarly, according to the European Society of Cardiology in high-income nations, the median number of cardiologists per million inhabitants was 99.0 compared with 61.1 in middle-income nations.
Further, according to the Cardiologists Society of India (CSI), there are merely 5500 cardiologists in the country with a population of 1.3 billion, and there is only one cardiologist for the 30, 000 inhabitants in the nation. Again, according to a recent investigation from the Association of American Medical Colleges (AAMC), by 2034, the nation is predicted to be lacking anywhere from 37,000 to 124,000 medics. This contains a deficit of 17,000 to 48,000 primary care doctors and 3,000 to 13,000 experts, a category that encloses cardiologists.
The global intracardiac echocardiography devices market is segmented based on product type, imaging type, application, end-user and region.
3D Imaging Type Expected to Dominate Market
The increasing adoption of 3D intracardiac echocardiography (ICE) is expected to boost segmental growth enabling the segment to hold a majority of market share in the forecast period. For instance, in September 2022, Baptist Health's Miami Cardiac and Vascular Institute employed the VeriSight Pro, a real-time 3D intracardiac echocardiography catheter from Philips. The technology delivers exceptional 2D and 3D live imaging suggestions for a broad spectrum of cardiac operations in structural heart conditions.
Similarly, in December 2021, the Children's Hospital Colorado (Children's Colorado) was the foremost pediatric clinic in the globe to employ a 3D intracardiac echocardiography (ICE) catheter in the therapy of congenital heart conditions in the Cardiac Catheterization Lab. The live, 3D picture direction delivered by the FDA-authorized technology from Phillips permits cardiac interventionalists to sufficiently guide complicated operations, which is anticipated to result in enhanced outputs.
Geographical Penetration
Increasing Number of Cardiovascular Disorders Cases in North America
Owing to the growing cases of cardiovascular diseases in North America the region is expected to dominate the global market throughout the forecast period. For instance, according to the CDC, cardiac condition is the top reason for mortality of males, females, and individuals of most ethnical and racial levels in the United States, one individual dies every 33 seconds in the United States from cardiovascular condition.
Similarly, almost 695,000 individuals in the United States died from heart conditions in 2021 accounting for 1 in every 5 deaths. Further, the heart condition cost the United States around $239.9 billion annually from 2018 to 2019, which includes the expense of healthcare assistance, medications, and failed productivity because of death. Further, the American Heart Association has published the Heart and Stroke Statistics 2022 Update, according to that report, cardiac arrest remains a public health emergency as are over 356,000 out-of-hospital cardiac arrests (OHCA) yearly in the U.S., and almost 90% of them are deadly.
The incidence of EMS-assessed non-traumatic OHCA in individuals of any age is assessed to be 356,461, or almost 1,000 individuals every day. Survival to hospital release after EMS-treated cardiac arrest declines by approximately 10%. Additionally, in 2022, an estimated 655,000 Americans were expected to die because of heart conditions, and over 140,000 were expected to die from stroke. Accounting for one in every four deaths in the U.S. Heart condition and stroke also account for over $320 billion in healthcare expenses and failed productivity per year.
The COVID-19 pandemic had deep effects on cardio-pulmonary health and healthcare delivery. Direct effects enclosed information on myopericarditis jointly with highly regular information on pneumonia and pulmonary fibrosis, periodically advancing to respiratory collapse and demise. Additionally unpredictable, nevertheless, were the indirect effects of the pandemic on CV examinations and hospital admissions which have repeatedly demonstrated varying drops.
While there has been no indication of actual declines in the preponderance of CVD or the incidence of acute coronary syndromes, these reductions have extended considerations that the pandemic has directed to general under-investigation and under-treatment of many individuals. Indeed, reports from respective nations suggest substantial declines in investigative procedures for heart failure and coronary and electrophysiological conditions in 2020 corresponded with 2019. Declines in hospital admissions for a degree of CV conditions, including ST-elevation myocardial infarction, have even been registered in the same period.
The major global players in the market include Johnson & Johnson Services Inc., GE HealthCare, Koninklijke Philips N.V., Siemens Healthcare, Abbott Laboratories, Boston Scientific Corporation, Infraredx Inc., Terumo Corporation, ESAOTE SPA, and Conavi Medical among others.
The global intracardiac echocardiography devices market report would provide approximately 61 tables, 58 figures and 186 Pages.
LIST NOT EXHAUSTIVE